

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: www.ajoonibiotech.com E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

December 09, 2024

To, National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Subject: Submission of Outcome of the Board Meeting held on Wednesday, November 13, 2024, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 in Machine Readable Format

SYMBOL: AJOONI

Dear Sir/Madam,

With reference to the above captioned subject, we hereby again submit the un-audited Financial Results for the quarter and half year ended September 30, 2024 which were approved in the Board Meeting held on Wednesday, November 13, 2024 in machine readable format.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You, Yours Truly, For Ajooni Biotech Limited

Jasjot Singh Managing Director DIN: 01937631



Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.) Phone: 0172-5020758-69 Website: www.ajoonibiotech.com E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

November 13, 2024

To, National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400051

Subject: Outcome of the Board Meeting held on Wednesday, November 13, 2024, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.

SYMBOL: AJOONI

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Wednesday, November 13, 2024 at 02.30 p.m concluded at 03.30 p.m. Following transactions were considered and approved:

- 1. The un-audited Financial Results for the quarter and half year ended September 30, 2024.
- 2. Limited Review Report for the quarter and half year ended September 30, 2024.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited
JASJOT Digitally signed by JASJOT SINGH
SINGH Date: 2024.11.13
15:32:40 +05'30'
Jasjot Singh

Managing Director DIN: 01937631

W 1 07 B 110 44404 B 111 NIBIA

QUARTER ENDED 30TH SEPTEMBER 2024 (In Lak QUARTER ENDED 30192023 (UnArdited) 31.03. QUARTER ENDED (Unardited) 31.03. 4 2,565.85 1,947.99 5,138.29 4,048.26 8 3.09.2023 34.63 36.22 36.22 36.22 36.65 0 6.77 (3.18) 6.5 1.5.00 7.77 (3.18) 6.5 1.5.00 7.77 (3.18) 6.5 1.5.00 7.77 (3.18) 6.5 1.5.00 7.77 (3.18) 6.5 1.5.00 7.77 (3.18) 6.5 1.5.00 7.77 (3.18) 6.5 1.5.00 7.77 (3.18) 7.75 (3.18) 6.5 1.5.00 7.77 (3.18) 7.75			CIN: L851	: L85190PB2010PLC040162	C040162			
COUNTYTER ENDED		STATEMENT OF STANDALONE FIN	ANCIAL RESULT	S FOR THE Q	UARTER END	111111111111111111111111111111111111111	TEMBER 202	4 (In Lakhs)
2,572.44 2,565.85 1,947.99 5,138.29 4,048.26 8 2,572.44 2,565.85 1,947.99 5,138.29 4,048.26 8 30.96 2,572.44 2,565.85 1,947.99 5,138.29 4,048.48 8,222 2,603.40 2,569.52 1,947.99 5,172.92 4,048.48 8,222 2,247.25 2,248.65 1,743.89 4,495.90 3,646.60 6, 6 9,41 1,502 1,502 1,919 20,92 32,57 168.50 15.02 1,919 20,92 32,57 168.50 15.29 1,924.91 5,030.85 3,992.97 7, 7 168.50 15.20 1,924.91 5,030.85 3,992.97 7, 7 1,07 1,07 1,520 1,240.07 91,51 2, 50 1,07 1,07 1,520 1,520 1,520 1,07 1,07 1,520 1,520 1,520 1,07 1,07 1,520 1,540.07 1,520 1,07 1,07 1,000.00 1,000 1,000.00 1,000.00 1,000 1,000 1,000.00 1,000 1,000.00 1,000.00 1,000 1,000.00 1,000.00 1,000 1,000.00 1,000.00		PARTICULARS		QUARTER	ENDED			Year Ended
2,572,44			30.09.2024	30.06.2024	30.09.2023	Period Ended (UnAndited)	Period Ended (UnAudited)	31.03,2024
2,572,44 2,565.85 1,947.99 5,138.29 4,048.26 8 30.96 3,67 29.00 3,463 3,622 2,603.40 2,569.52 1,976.99 5,172.92 4,084.48 8,8 2,247.25 2,248.65 1,743.89 4,495.90 3,646.60 6,9 9,41 (1.64) 15.90 7.77 (3.18) 70,31 57.28 51.08 127.59 104.71 5,90 15.02 21.34 44.88 42.25 22,56 22.32 21.34 44.88 42.25 2,523.93 2,506.92 1,924.91 5,030.85 3,992.97 79,47 62.60 52.08 142.07 91.51 19,07 15.20 12.50 12.50 12.50 19,07 15.20 12.50 12.50 12.50 19,07 15.20 12.50 12.50 19,07 15.20 12.50 12.50 12.50 19,07 15.20 12.50 12.50 19,07 15.20 12.50 12.50 19,07 15.20 12.50 12.50 11,15.65 46.82 40.47 177.92 80.66 2 11,15.65 46.82 40.47 175.92 12.50 115.65 46.82 40.47 175.92 12.50 115.65 46.82 40.47 175.92 12.50 115.65 46.82 40.47 175.92 12.50 115.65 46.82 40.47 175.92 12.50 115.65 46.82 40.47 175.92 12.50 115.65 46.82 40.47 175.92 12.50 115.65 46.82 40.47 175.92 12.50 115.65 40.47 175.92 12.50 115.65 40.47 175.97 12.50	-	подпа				30.09,2024	30.09.2023	
1,000 1,00	1 2	evenue from operations	C C C C C C C C C C C C C C C C C C C	20000				
2,603.40 2,569.52 1,976.99 5,172.92 4,084.48 8 8 2,172.92 4,084.48 8 8 2,172.92 4,084.48 8 8 1,743.89 4,495.90 3,646.60 6, 9.41 (16.4) 15.90 15.02 15.02 15.03 15.02 15.03 15.02 15.03 15.	0	liher moome	45,276,2	2,202.83	1,947.99	5,138.29	4,048.26	8,011.46
Columbia		otal income from operations	2 603 40	7 560 57	1 076 00	34.63	36.22	219.33
2,247.25	压	xpenses		70.0067	1,7 (0.33	3,114.94	4,084.48	8,230.7
941	Q	ost of Material Consumed	2,247.25	2,248.65	1.743.89	4 495 90	3 646 60	6.096.3
70.31 57.28 51.08 127.59 104.71 1 5.90	C	hange In Inventories	9.41	(1.64)	15.90	7.77	(3.18)	186
5.90 15.02 19.19 20.92 32.57 22.56 22.32 21.34 44.88 42.25 168.50 165.29 73.51 333.79 170.02 25.523.93 2,506.92 1,924.91 5,030.85 3,992.97 7,9 4 tax 79.47 62.60 52.08 142.07 91.51 19.07 15.20 12.50 12.50 12.50 -1.11 0.58 0.89 1.65 (1.65) 61.51 46.82 40.47 127.92 80.66 2 54.14 (162.77) (1 61.56 46.82 40.47 182.06 (82.11) 1 61.60 61.51 46.82 40.47 182.06 (82.11) 1 61.60 61.	II	mployee benefit expenses	70.31	57.28	51.08	127.59	104.71	180 0
168.56 165.29 73.51 333.79 170.02 168.50 165.29 73.51 333.79 170.02 168.50 165.29 73.51 333.79 170.02 15.20 15.20 12.50 12.50 19.07 15.20 12.50 12.50 -1.11 0.58 0.89 1.65 (1.65) 61.51 46.82 40.47 127.92 80.66 54.14 62.60 54.14 (162.77) (162.77) 15.60 12.50 12.50 12.50 15.60 12.50 12.50 16.70 16.82 40.47 182.06 (82.11) 16.60 33.44.87 1752.27 3.444.87 1752.27 16.80 1.65 1.752.27 3.444.87 1752.27 16.80 1.65 1.752.27 3.444.87 1752.27 16.80 1.65 1.752.27 3.444.87 1.752.27 16.80 1.60 (82.11) 1.752.27 16.80 1.60 (82.11) 1.65 1.752.27 16.80 1.60 (82.11) 1.752.27 16.80 1.60 (82.11) 1.65 1.752.27 16.80 1.752.27 1.752.27 1.752.27 16.80 1.752.27 1.752.27 1.752.27 16.80 1.752.27 1.752.27 1.752.27 16.80 1.752.27 1.752.27 1.752.27 16.80 1.752.27 1.752.27 1.752.27 16.80 1.752.27 1.752.27 1.752.27 16.80 1.752.27 1.752.27 1.752.27 16.80 1.752.27 1.752.27 16.80 1.752.27 1.752.27 16.80 1.752.27 1.752.27 16.80 1.752.27 1.752.27 17.80 1.752.27 1.752.27 17.80 1.752.27 1.752.27 17.80	11	inance costs	5.90	15.02	19.19	20.92	32.57	55.60
168.50 165.29 73.51 333.79 170.02 1523.93 2,506.92 1,924.91 5,030.85 3,992.97 7,70.02 1520 15.20 12.50 12.50 12.50 19.07 15.20 12.50 12.50 12.50 19.07 15.20 12.50 12.50 12.50 19.07 15.20 12.50 12.50 12.50 19.07 15.20 12.50 12.50 12.50 19.07 15.20 12.50 12.50 12.50 19.07 15.20 12.50 12.50 12.50 11.50 12.50 12.50 12.50 12.50 11.50 12.50 12.50 12.50 12.50 11.50 12.50 12.50 12.50 12.50 12.50 11.50 12.50	0	epreciation and amortization expenses	22.56	22.32	21.34	44.88	42.25	87.77
dtax 2,523.93 2,506.92 1,924.91 5,030.85 3,992.97 7 dtax 79.47 62.60 52.08 142.07 91.51 79.47 62.60 52.08 142.07 91.51 19.07 15.20 12.50 12.50 12.50 -1.11 0.58 0.89 1.65 (1.65) 61.51 46.82 40.47 127.92 80.66 54.14 (162.77) (1 61.55 46.82 40.47 182.06 (82.11) 1 61.66 (82.11) 1	D	syment to NSE					79:4	7.70
dtax 79.47 62.60 52.08 142.07 91.51 79.47 62.60 52.08 142.07 91.51 19.07 15.20 12.50 12.50 12.50 -1.11 0.58 0.89 1.65 (1.65) 61.51 46.82 40.47 127.92 80.66 54.14 (162.77) (162.77	0	ther expenses	168.50	165.29	73.51	333.79	170.02	573 03
d tax 79.47 62.60 52.08 142.07 91.51 2 19.07 15.20 12.50<	E	otal expenses	2,523.93	2,506.92	1,924.91	5.030.85	3.992.97	7 931 18
19.07 15.20 12.5	1	rofit/(Loss) before exceptional items and tax	79.47	62.60	52.08	142.07	91.51	200 61
19.07 15.20 12.5	田	cceptional items					10.17	10.667
19.07 15.20 12.50	D	ofit/(Loss) before tax	79,47	62.60	52.08	142.07	01 51	2000
19.07 15.20 12.5		х ехреплев					16.17	477.01
61.51 46.82 40.47 127.92 80.66 2 54.14 - 54.14 (162.77) (10 61.55	3	Current tax	19.07	15.20	12.50	12.50	12.50	07.50
61.51 46.82 40.47 127.92 80.66 2 54.14 - 54.14 (162.77) (11 6dyear 115.65 46.82 40.47 182.06 (82.11) 11 6the 60.00 (82.11) 1.752.27 3.444.87 1.752.27	6	Deferred tax	-1.11	0.58	0.80	1.65	0.21	06.30
61.51 46.82 40.47 127.92 80.66 54.14 - 54.14 (162.77) d/year 115.65 46.82 40.47 182.06 (82.11)	3	Mat Credit			200	CO.T	(00.1)	(4.01
64.14 - 54.14 (162.77) 64.14 (162.77) 64.14 (162.77) 64.14 (162.77) 64.14 (162.77) 74.14 (162.77) 74.14 (162.77)	7	t Prolit/(Loss) for the period/year	61.51	46.82	40 47	127.02	22 00	07.7.6
ve income 54.14 - 54.14 (162.77) ome for the period/year 115.65 46.82 40.47 182.06 (82.11) and all face value of the 54.14 (162.77) and an	ನ	her comprehensive income (net of tax)				141.72	00.00	71.012
ve income 54.14 (162.77) ome for the period/year 115.65 46.82 40.47 182.06 (82.11) of the state of the control of the	0.5	;s:	54.14		T.	54.14	(162.77)	(103.22)
ome for the period/year 115.65 46.82 40.47 182.06 (82.11)	12	tal other comprehensive income	54.14			23.14	(A. M. 4) (2)	
oital (face value of the 83 444.87 1.752.27 3.444.87 1.752.27	2 5	tal comprehensive income for the period/year II+VIII)	115.65	46.82	40.47	182.06	(104.77)	113.00
マンプー	E E	oital (face value of th	0000	3,444.87	1.752.27	3,444.87	1.752.27	1 752 27

X.	XI Other equity (excluding revaluation reserve)	5,167.57	5,104.74	2,332,55	5 167 57	32 523 6	11 013 0
×	EPS in Rs. (Face Value of Rs.10/- each)*			2011	3,201.31	4,334.33	7,518.51
	-Basic	0.04	0.03	25.0		200	
	-Diluted		0.00	0.73	0.04	0.46	0.25
Make		0.04	0.03	0.23	0.04	0.46	300
1. The its mee	1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 12.11.2024 after being reviewed by the Audit Committee.	e SEBI (LODR) Regul d by the Audit Comm	ations, 2015 as a ottee.	mended and have	been taken on	record by Board	of Directors at
2. The the Co	2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.	dance with IND AS 10	8 "operating seg	ments". and there	efore segment re	porting is not a	oplicable to
3. Du	3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.	licability of IND-AS,	there has been a	difference in the	figures as repor	ted earlier.	
Place	JASJOT Digitally signed by JASJOT SINGH SINGH 15:32:51+05'30' Togate : 13.11.2024 15:32:51+05'30'		Fr. Jan. M. Di.	For Ajoon BAOO Managing Street DIN: 01937631	81078C		



Regd. Office: D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

CASI	H FLOW STATEMENT FOR THE HALF YEAR EN	DED 30TH	SEPTEM	BER 2024
			A	Amount in Rs. (Lakhs)
"A" (1)	CASH FLOW FROM OPERATING ACTIVITIES			
	Profit/(Loss) Before Tax		1	61.51
	Adjustments for:		1	
	Depreciation & Amortization	22.56		
	Interest & Finance Charges	5.90		
	Interest Income	-30.86	(2.40)	
	Operating Profit before Working Capital Changes			59.11
	Adjustments for:			
	Decrease/(Increase) in Receivables	-1,037.49		
	Decrease/(Increase) in Inventories	-159.44		
	Decrease/(Increase) in Loans and Other Advances	-1,035.46		
	Decrease/(Increase) in Other Current Assets	-18.39		
	Increase/(Decrease) in Trade Payables	-158.45		
	Increase/(Decrease) in Other Current Liabilities	59.09	-2,350.13	
	Cash generated from operations			(2,291.02)
	Tax paid prev year			
	Net Cash flow from Operating activities			(2,291.02)
	(2) CASH FLOW FROM INVESTING ACTIVITIES			
	Purchase of Tangible Assets/ Intangible			
1	Assets/ Capital Work-In-Progress		-64.47	
1	(Increase)/Decreaseby sale/purchase in Non-Currer	t Investmer	-244.26	
	Interest Income	1	30.86	
	Net Cash used in Investing activities			-277.87
	(3) CASH FLOW FROM FINANCING ACTIVITIES			
	Proceeds from/ (Repayment) of Long term Borrowin	ngs	51.39	
	Proceeds from issue of share capital		1,692.60	
1	premium received	1	2,538.39	l

	Increase/(Decrease) in Short Term Borrowings Interest and Other Finance Costs paid	-48.57 (5.90)	
	Net Cash used in financing activities		4,227.90
"B"	Net increase in cash & Cash Equivalents		1,659.01
	Add: Cash and Cash equivalents at the Beginning of the Year 1.04.2024		42.82
"c"	Cash & Cash Equivalents at 30.09.2024		1,701.83



JASJOT by JASJOT SINGH Date: 2024.11.13 15:33:04 +05'30'



Regd. Office: D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)
Phone: 0172-5020758-69 Website: www.ajoonibiotech.com
E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

Statement of Assets and Liabilities For the Year ended on 30th SEPTEMBER 2024

PARTICULARS	ACTIVI COM	in Rs. (Lakhs)
I. ASSETS	30TH SEP 2024	31ST MARCH 2024
(1) Non - Current Assets a) Property, Plant and Equipment b) Capital Work In Progress c) Investment Property d) Goodwill e) Other Intangible Assets f) Intangible Assets Under Development g) Biological Assets other than Bearer Plants	994.17 106.60	1,031.89 92.45 - -
h) Financial Assets (1) Investments (2) Trade Receivables (3) Loans (4) Other Financial Assets	433.91	213.63 - -
i) Deffered Tax Asset (net) j) Other Non Current Asset	32.33 200.00	31,22 150.00
(2) <u>Current Assets</u> a) Inventories b) Financial Assets (1) Investments	1,696.17	1,536.73
(2) Trade Receivables (3) Cash & Cash Equivalent (4) Bank Balances other than (iii) above	2,333.43 1,701.83	1,295.94 42.82
(5) Loans (6) Other Financial Asset c) Current Tax Assets (net)	1,386.88	351.42 0.00
d) Other Current Asset	24.32	5.93

O(HUMALI)

Works: G.T. Road, Khanna-141401 (Punjab) INDIA

TOTAL	8,909.64	4,752.04
II EQUITY AND LIABILITIES		-
(1) Equity		
a)Equity Share Capital	3,444.87	1,752.27
b) Other Equity	5,167.57	
	3,107.37	2,518.51
(2) Non-Current Liabilities		1
a) Financial Liabilities		
(1) Borrowings	219.59	168,20
(2) Trade Payables	217.39	168.20
(3) Other Financial Liabilties		
b) Employee Benefit Obligations	13.04	11.99
c) Deferred Tax Liability (net)	10.01	11.99
d) Other Non Current Liability		-
3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	0.00	
(2) Trade Payables	0.00	48.57
(3) Other Financial Liabilities	0.00	158.45
b) Employee Benefit Obligations	1	
c) Other Current Liabilities	. 0.95	1.05
d) Current tax liabilities (Net)	44.55	5.48
Janean an Habilities (Net)	19.07	87.50
TOTAL	8,909.64	4,752.04

Place: Mohali Date: 13.11.2024 For Ajooni Biotech Limited
MOHALI
Jasjot Singh

* Managing Director

DIN: 01937631

JASJOT Digitally signed by JASJOT SINGH Date: 2024.11.13 15:33:16 +05'30'



SCO 65-B (1st Floor) City Heart, Kharar Chandigarh Road,

Kharar, SAS Nagar Mohali-140301 Mobile: 98154 50065

Email : nkgargcal@yaheo?cb.in

Limited Review Report

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 30th September, 2024.(the Statement) attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended), Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly,

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

rtered Accounta

For NARINDER KUMAR AND COMPANY

Chartered Accountants

Charund (NARINDER KUMAR GARG)

PARTNER M.NO-080287

Date:-13.11.2024

UDIN:- 24080287BKBLOC9555